DiaCarta said Monday that it has formed a strategic partnership with New Jersey-based contract research organization Hopkins MedTech Compliance/Hopkins MedTech Lab Services to provide validation and regulatory compliance services for laboratory test and in vitro diagnostic developers in the US.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has entered into a software development partnership with BYG4lab®, a leading provider of middleware and data management solutions for laboratories, that intends to accelerate QuidelOrtho’s efforts to expand and strengthen informatics offerings across its portfolio of diagnostics platforms.

On July 19, 2023, the Third People’s Hospital of Shenzhen (hereinafter referred to as Shenzhen Third Hospital) and Shenzhen New Industries Biomedical Engineering Co., Ltd. (hereinafter referred to as Snibe) successfully held an exchange seminar and a signing ceremony of strategic cooperation on “Industry-University-Research-Hospital-Application”.

On July 19, Mindray and Beijing Strong Biotechnologies, Inc. (hereinafter referred to as BSBE) held a strategic cooperation signing ceremony at Mindray` s headquarters in Shenzhen.

Next-generation sequencing data analysis platform company One Codex said on Thursday that it has formed a partnership with Swiss clinical product manufacturer 4bases to bring sample-to-report microbiome analysis solutions to clinicians in the EU.

Thailand is a country with a high prevalence of thalassemia and sickle-cell anemia, and the related hemoglobinopathies have become a prominent problem in Thailand's public health.

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

A partnership between Quest Diagnostics and Envision Sciences has introduced a new prostate cancer biomarker test.

Tempus, a leader in artificial intelligence and precision medicine, announces its GEMINI Non-small Cell Lung Cancer (NSCLC) study (NCT05236114). The Tempus-sponsored study, being run in collaboration with AstraZeneca, aims to create a robust multi-omic dataset for patients with NSCLC to facilitate future novel research related to precision medicine, diagnostic development, and biomarker discovery.

Beijing Hotgen Biotech Co., Ltd（688068.SH）released an announcement on July 6, the company intends to use its own funds together with Qingdao Chuangjing Private Equity Fund Management Co., Hangzhou Bioer Technology Co.,Ltd, Anhui Yaoan Investment Group Co. and Shaoxing Guochuang Zhende Medical (603301) Industry Phase I Equity Investment Partnership (Limited Partnership) co-finance and participate in the investment in Tristar Conrad.